Company profile: Curetis
1.1 - Company Overview
Company description
- Provider of molecular diagnostic tools for severe infectious diseases, offering the Unyvero Platform with multiplex PCR and broad panels for pathogen and resistance gene detection. Solutions include the integrated Unyvero System (L4 Lysator, C8 Cockpit, A50 Analyzer), application cartridges for syndromic testing, and the Unyvero A50 rapid solution delivering results in less than 5 hours.
Products and services
- Unyvero Platform: A multiplex PCR-based molecular diagnostics platform integrating a laboratory into one instrument, delivering multiparameter detection of pathogens and resistance genes for severe bacterial infections via application-specific Unyvero Cartridges
- Unyvero Application Cartridge: A microarray-enabled consumable containing DNA isolation, amplification, and detection components, using multiplex PCR for syndromic testing with broad panels covering pathogens and resistance gene markers
- Unyvero System: An instrument-integrated setup comprising the L4 Lysator for sample lysis, C8 Cockpit for control and result management, and A50 Analyzer that processes application cartridges independently
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Curetis
BioIVT
HQ: United States
Website
- Description: Provider of biological and in vitro products and services for biopharmaceutical, diagnostic, and biotechnology organizations. Offerings include in vivo ADME/PK studies, bioanalytical services, biospecimen characterization, consulting for drug R&D, long-term hepatocyte culture systems (HEPATOPAC and HEPATOMUNE), and Human AB Serum for cell culture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioIVT company profile →
Foresight Diagnostics
HQ: United States
Website
- Description: Provider of liquid biopsy-based cancer detection and monitoring solutions leveraging patient-specific phased variants, including Foresight CLARITY MRD assays for lymphoma and solid tumors; the PhasED-Seq high-sensitivity ctDNA test; MRD-driven clinical trials; a ctDNA research assay to quantify and monitor disease burden; and customizable SNV and CNV genotyping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foresight Diagnostics company profile →
Scribe Therapeutics
HQ: United States
Website
- Description: Provider of CRISPR-based therapeutic platforms and medicines, including X-Editing (XE) technologies for high-activity, specific, deliverable gene editing; CRISPR by Design optimization; ELXR CasX-based epigenetic repressors; in vivo CRISPR genetic medicines (e.g., for sickle cell) with non-viral delivery; and ex vivo natural killer (NK) cell therapies for cancer in collaboration with Sanofi.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scribe Therapeutics company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
Medicinal Genomics
HQ: The Netherlands
Website
- Description: Provider of genomics-driven testing and breeding solutions for medical cannabis and hemp, including the PathoSEEK qPCR-based microbial safety testing platform and detection assays for flower, extracts, and infused products; SenSATIVAx DNA purification kits; FemINDICAtor qPCR plant sex testing; and genomic services to identify markers for desirable traits and accelerate breeding programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medicinal Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Curetis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Curetis
2.2 - Growth funds investing in similar companies to Curetis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Curetis
4.2 - Public trading comparable groups for Curetis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →